AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics
company, has announced the results of two large scale clinical
studies, which show that the company's Nu.Q® assays, when used in
conjunction with the Fecal Immunochemical Test (FIT), can detect
colorectal cancer and all high-risk advanced adenomas in
symptomatic patients, and thereby reduce unnecessary colonoscopies.
The studies also demonstrated that the company's Nu.Q® assays can
improve the detection of high-risk adenomas in asymptomatic
patients.
Principal Investigator, Professor Han-Mo
Chiu, National Taiwan University, said "We are enormously
encouraged by the findings of these two studies. Not only do they
show that using Nu.Q® assays in combination with FIT can
potentially reduce unnecessary colonoscopies by up to 28% in
patients with gastrointestinal symptoms, the studies also show that
this dual approach could be used more widely to improve the
effectiveness of FIT-based screening programs targeting
asymptomatic patients. We look forward to presenting our findings
to colleagues at ASCO GI 2022."
Dr. Marielle Herzog, Research and
Development Director at Volition, said "Early diagnosis is key to
improving outcomes for patients with colorectal cancer, and cancer
screening programs are critical to every public health system. The
results of our studies, using Volition's Nu.Q® assays in
conjunction with FIT, are incredibly encouraging, not only in
reducing unnecessary colonoscopies but also in detecting high-risk
adenomas, both proximal and distal, which FIT, when used alone can
miss. We are excited about the next stage, facilitating an
independent, prospective validation study later this year."
The studies were undertaken by Volition and the Department of
Internal Medicine at the National Taiwan University Hospital and
findings will be presented at the 2022 ASCO Gastrointestinal
Cancers Symposium, later this week.
Volition is developing simple, easy to use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer.
Colorectal cancer is the fourth most common cancer worldwide,
with 1.9 million new cases in 2020, and accounts for over 9% of all
cancer-related deaths each year¹. Population-based colorectal
cancer screening programs are in place in many healthcare systems
globally, and the most commonly recommended screening method² is
the FIT, followed up with colonoscopy, an invasive visual
examination. However, approximately 60% of FITs provide
false-positive results³, leading to unnecessary and costly
colonoscopies.
Posters to be presented at ASCO GI 2022 can be downloaded
here:
1) Circulating nucleosomes levels improve FIT performance
for detecting high-risk colorectal neoplasms in a symptomatic
population.
2) Circulating nucleosomes for detection of colorectal cancer
and high-risk advanced adenomas.
For more information about Volition's Nu.Q® technology go to:
www.volition.com
Notes to editors:
References:
¹ World Health Organization International Agency for Research on
Cancer (IARC). GLOBOCAN 2020: estimated cancer incidence, mortality
and prevalence worldwide in 2020.
² Schliemann, D., Ramanathan, K., Matovu, N. et
al. The implementation of colorectal cancer screening
interventions in low-and middle-income countries: a scoping
review. BMC Cancer 21, 1125
(2021).
³ Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal
immunochemical testing in reducing colorectal cancer mortality from
the One Million Taiwanese Screening Program. Cancer.
2015;121(18):3221-3229.
About the studies
- 476 patients referred for surveillance colonoscopy or secondary
to bowel symptom were enrolled: (i) CRC (n= 67), (ii) advanced
adenoma (AA) (n=60), non-AA (n=123); (iv) non-neoplastic polyps
(n=29); (vi) colonoscopy negative (controls) (n=197).
- 520 average-risk asymptomatic patients: (i) CRC (n= 33), (ii)
advanced adenoma (AA) (n=123, including 18 with AA>2cm); (iii)
non-AA (n=168); (iv) non-neoplastic polyps (n=30); (vi) colonoscopy
negative control (n=166).
- Plasma and stool samples were obtained prior to
colonoscopy.
- Circulating Nucleosome levels measured using Volition's Nu.Q®
quantitative immuno-assays.
- FIT: OC-SENSOR (Eiken Chemical Co., Ltd., Tokyo, Japan) using a positive cut-off of
20ug/g feces.
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential to not
only prolong the life of patients, but also to improve their
quality of life. The tests are based on the science of
Nucleosomics™, which is the practice of identifying and measuring
nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present. Volition is primarily focused
on human diagnostics and monitoring but also has a subsidiary
focused on animal diagnostics and monitoring.
Volition's research and development activities are centered in
Belgium, with a small laboratory
in California and additional
offices in Texas, London, and Singapore, as the company focuses on bringing
its diagnostic and disease monitoring products to market.
For more information about Volition, visit Volition's website
volition.com or connect with us via:
- Twitter: https://twitter.com/volitionrx
- LinkedIn: https://www.linkedin.com/company/volitionrx
- Facebook: https://www.facebook.com/VolitionRx/
- YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Debra Daglish,
Volition
mediarelations@volition.com
+44 (0)
20 3872 3954
|
Scott Powell,
Volition
investorrelations@volition.com
+1 (646) 650
1351
|
Jen Lewis,
Mind&Matter
Jen.Lewis@ashfieldhealth.com
+44 (0)7809
867943
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "can," "could,"
"would," "should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of Volition's blood-based diagnostic,
prognostic and disease monitoring tests, Volition's ability to
develop and successfully commercialize such test platforms for
early detection of cancer and other diseases as well as serving as
a diagnostic, prognostic or disease monitoring tools for such
diseases, and the timing of product launches and publications.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties, including, without limitation, results of
studies testing the efficacy of its tests. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic, prognostic or disease monitoring
products Volition might develop; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks
identified in Volition's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as other documents that
Volition files with the Securities and Exchange Commission. These
statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-presents-study-data-at-asco-gi-2022-on-circulating-nucleosomes-for-the-detection-of-colorectal-cancer-and-high-risk-advanced-adenomas-301464863.html
SOURCE VolitionRx Limited